CO6321263A2 - Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a - Google Patents

Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a

Info

Publication number
CO6321263A2
CO6321263A2 CO10159483A CO10159483A CO6321263A2 CO 6321263 A2 CO6321263 A2 CO 6321263A2 CO 10159483 A CO10159483 A CO 10159483A CO 10159483 A CO10159483 A CO 10159483A CO 6321263 A2 CO6321263 A2 CO 6321263A2
Authority
CO
Colombia
Prior art keywords
provides
subject
compound
formula
effective amount
Prior art date
Application number
CO10159483A
Other languages
English (en)
Inventor
Andreas Ritzen
Jan Kehler
Morten Langgard
Jacob Nielsen
John Paul Kilburn
Mohamed M Farh
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6321263A2 publication Critical patent/CO6321263A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Esta invención se dirige a compuestos que son inhibidores de la enzima PDE10A. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para la preparación de los compuestos de fórmula I. La presente invención proporciona además un método para tratar un sujeto que sufre un trastorno neurodegenerativo, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I. La presente invención asimismo proporciona un método para tratar un sujeto que sufre una adicción a las drogas, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I. La presente invención también proporciona un método para tratar un sujeto que sufre un trastorno psiquiátrico, que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de fórmula I.
CO10159483A 2008-06-20 2010-12-20 Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a CO6321263A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800855 2008-06-20
DKPA200900402 2009-03-24
DKPA200900519 2009-04-22

Publications (1)

Publication Number Publication Date
CO6321263A2 true CO6321263A2 (es) 2011-09-20

Family

ID=40902594

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10159483A CO6321263A2 (es) 2008-06-20 2010-12-20 Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a

Country Status (28)

Country Link
US (1) US8841297B2 (es)
EP (1) EP2318394B1 (es)
JP (1) JP5930714B2 (es)
KR (3) KR20170016523A (es)
CN (2) CN102124002B (es)
AR (1) AR072199A1 (es)
AU (1) AU2009259209B2 (es)
BR (1) BRPI0915383B8 (es)
CA (1) CA2728335C (es)
CL (2) CL2010001467A1 (es)
CO (1) CO6321263A2 (es)
CY (1) CY1115001T1 (es)
DK (1) DK2318394T3 (es)
EA (2) EA018880B1 (es)
ES (1) ES2456349T3 (es)
HK (1) HK1159632A1 (es)
HR (1) HRP20140232T1 (es)
IL (1) IL209834A (es)
MX (1) MX2010014136A (es)
MY (1) MY152949A (es)
NZ (1) NZ589926A (es)
PL (1) PL2318394T3 (es)
PT (1) PT2318394E (es)
RS (2) RS53226B (es)
SI (1) SI2318394T1 (es)
TW (1) TWI501965B (es)
WO (1) WO2009152825A1 (es)
ZA (1) ZA201100109B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) * 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
CN104710385B (zh) * 2010-03-12 2018-11-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JP5760085B2 (ja) * 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
WO2012018058A1 (ja) * 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
PL2637704T3 (pl) * 2010-11-10 2015-08-31 H Lundbeck As Radioznakowane ligandy oparte na fenyloimidazolu
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US8349824B2 (en) 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
US9540379B2 (en) * 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2013005798A1 (ja) * 2011-07-06 2013-01-10 持田製薬株式会社 新規含窒素複素環誘導体
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
SG11201406890YA (en) * 2012-05-30 2014-11-27 Hoffmann La Roche Triazolo compounds as pde10 inhibitors
JP6236439B2 (ja) * 2012-06-19 2017-11-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9556179B2 (en) 2012-12-21 2017-01-31 Bristol-Myers Squibb Company Substituted imidazoles as casein kinase 1 D/E inhibitors
AU2014221799B2 (en) * 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2902806T3 (es) 2014-04-23 2022-03-29 Dart Neuroscience Llc Composiciones que contienen compuestos de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo sustituidos como inhibidores de PDE2
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
PL408251A1 (pl) * 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
BR112020013743A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S hemiadipato de 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina
WO2020094592A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments
CN110981813A (zh) * 2019-12-19 2020-04-10 西安近代化学研究所 一种2-氰基-5-芳基-1h-咪唑类化合物的合成方法
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036840A (en) 1972-06-07 1977-07-19 Icn Pharmaceuticals 2-Substituted-s-triazolo[1,5a]pyrimidines
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
EP1641794A1 (en) * 2003-06-30 2006-04-05 ALTANA Pharma AG Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
CA2556413A1 (en) * 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2005086895A2 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CA2643963A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors

Also Published As

Publication number Publication date
US8841297B2 (en) 2014-09-23
TWI501965B (zh) 2015-10-01
EA201170061A1 (ru) 2011-08-30
TW201000481A (en) 2010-01-01
NZ589926A (en) 2011-09-30
PL2318394T3 (pl) 2014-09-30
IL209834A0 (en) 2011-02-28
KR102025487B1 (ko) 2019-09-25
JP2011524381A (ja) 2011-09-01
BRPI0915383A2 (pt) 2015-11-03
KR20170016523A (ko) 2017-02-13
EA018880B1 (ru) 2013-11-29
DK2318394T3 (en) 2014-03-24
IL209834A (en) 2014-02-27
CA2728335A1 (en) 2009-12-23
BRPI0915383B1 (pt) 2020-09-15
PT2318394E (pt) 2014-04-03
CL2011003205A1 (es) 2012-06-22
ZA201100109B (en) 2012-03-28
RS53226B (en) 2014-08-29
JP5930714B2 (ja) 2016-06-08
KR20170134781A (ko) 2017-12-06
KR101703938B1 (ko) 2017-02-07
RS53704B1 (en) 2015-04-30
CA2728335C (en) 2016-05-24
EP2318394B1 (en) 2014-01-22
WO2009152825A1 (en) 2009-12-23
CN102124002A (zh) 2011-07-13
KR20110020845A (ko) 2011-03-03
ES2456349T3 (es) 2014-04-22
CY1115001T1 (el) 2016-12-14
EP2318394A1 (en) 2011-05-11
CL2010001467A1 (es) 2011-08-05
AU2009259209A1 (en) 2009-12-23
EA201270046A1 (ru) 2012-05-30
HK1159632A1 (en) 2012-08-03
CN102482262A (zh) 2012-05-30
EA021410B1 (ru) 2015-06-30
MX2010014136A (es) 2011-01-21
AU2009259209B2 (en) 2013-08-01
BRPI0915383B8 (pt) 2021-05-25
CN102482262B (zh) 2014-06-25
AR072199A1 (es) 2010-08-11
HRP20140232T1 (hr) 2014-04-11
CN102124002B (zh) 2014-06-25
MY152949A (en) 2014-12-15
US20120190685A1 (en) 2012-07-26
SI2318394T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
CO6321263A2 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
CO6612246A2 (es) Derivados de 2-arilimidazol como inhibidores de enzima pde10a
DOP2012000165A (es) Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a
DOP2012000169A (es) Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a
ECSP13012698A (es) Derivados de imidazol como inhibidores de la enzima pde10a
BR112015007731A2 (pt) pde9i com cadeia principal de imidazo pirazinona
ECSP14015609A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
DOP2013000108A (es) Derivados de imidazol como inhibidores de la enzima pde10a
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors

Legal Events

Date Code Title Description
FG Application granted